KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Other financing activities (2023)

Biocryst Pharmaceuticals' Other financing activities history spans 5 years, with the latest figure at $262000.0 for Q3 2023.

  • For Q3 2023, Other financing activities changed N/A year-over-year to $262000.0; the TTM value through Dec 2024 reached $262000.0, up 110.75%, while the annual FY2023 figure was $11.1 million, N/A changed from the prior year.
  • Other financing activities reached $262000.0 in Q3 2023 per BCRX's latest filing, up from -$1.2 million in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $262000.0 in Q3 2023 to a low of $262000.0 in Q3 2023.